Ads
related to: does simvastatin help with cholesterol management guidelines- Co-Pay Program
Resources
to Support Your Patients
- Trial Results
See Clinical Data
and Trial
- Resources
More Information
For Your Practice
- Request Samples
Get patients started
with a 14-day sample
- Co-Pay Program
clswitch.com has been visited by 10K+ users in the past month
Search results
Results From The WOW.Com Content Network
Simvastatin is an effective serum lipid-lowering drug that can decrease low density lipoprotein (LDL) levels by up to 50%. [citation needed] Simvastatin had been shown to interact with lipid-lowering transcription factor PPAR-alpha [36] and that interaction might control the neurotrophic action of the drug.
While there have been concerns about side-effects associated with statins (myopathy and rhabdomyolysis), these were rare in this study. [citation needed] The number needed to treat in the study was 57 to postpone one death and 19 to prevent one cardiovascular "event" (in those taking the drug simvastatin for 5 years). There was no mortality ...
The Scandinavian Simvastatin Survival Study (also known as the 4S study), was a multicentre, randomized, double-blind, placebo-controlled clinical trial, which provided the initial data that supported the use of the cholesterol-lowering drug, simvastatin, in people with a moderately raised cholesterol and coronary heart disease (CHD); that is people who had previously had a heart attack or angina.
Antihypertensive agents comprise multiple classes of compounds that are intended to manage hypertension (high blood pressure). Antihypertensive therapy aims to maintain a blood pressure goal of <140/90 mmHg in all patients, as well as to prevent the progression or recurrence of cardiovascular diseases (CVD) in hypertensive patients with established CVD. [2]
Niacin/simvastatin (trade name Simcor, by Abbott) is a combination drug consisting of an extended release form of the lipid-lowering drug niacin and the statin drug simvastatin. [1] It is used for the treatment of dyslipidemia. It was approved by the FDA on February 15, 2008. [2]
Ezetimibe reduces blood cholesterol by acting at the brush border of the small intestine and inhibiting the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver. Simvastatin is an HMG-CoA reductase inhibitor or statin. It works by blocking an enzyme that